Global Point of Care Fertility Testing Market Research Report - Segmented by Type (Human chorionic, Gonadotropin (HCG) urine test, FSH urine test, Human chorionic Gonadotropin (HCG) blood test, Luteinizing hormone (LH) urine test); By Fertility Tests (Line-Indicator, Digital); By Distribution Channel (Hypermarkets & supermarkets, Gynecology & Fertility clinics, Pharmacy, Online sales); By End-User (Hospitals & Clinics, Research Institutes, Diagnostic Laboratories); and Region - Size, Share, Growth Analysis | Forecast (2024 2030)

Point of Care Fertility Testing Market Size (2024-2030)

The Global Point of Care Fertility Testing Market is estimated to have reached a valuation of USD 1.4 billion in 2022 and is anticipated to attain a value of USD 1.98 billion by 2030, showcasing a growth rate of 4.4% during the forecast period of 2023-2030.

Point of Care Fertility

Point of care fertility testing refers to a type of medical examination conducted at or near the patient's treatment location, which could be at home, in a pharmacy, or a clinic. Individuals can monitor their reproductive health and strategically plan pregnancies through the utilization of point-of-care fertility testing. Various products, such as ovulation prediction kits, fertility monitors, sperm analyzers, and pregnancy tests, are employed for point-of-care fertility testing.

Global Point of Care Fertility Testing Market Drivers:

The declining fertility rates among both men and women serve as a significant driver for the demand for point-of-care fertility testing products:

Fertility rate, representing the average number of children a woman has throughout her lifetime, is influenced by a multitude of factors, encompassing biological, physiological, social, economic, and environmental elements. Factors like smoking, alcohol consumption, drug usage, obesity, stress, and chronic illnesses can contribute to reduced fertility in both genders. For example, smoking has been linked to diminished quantity and quality of male sperm, as well as an increased risk of infertility and miscarriage in females. Obesity can lead to decreased sperm quality and erectile dysfunction in males, and hormonal abnormalities and ovulation issues in females. Age also plays a role, with fertility decreasing notably after 35 for women and 40 for men. The use of contraception, sterilization, or abortion can influence family planning decisions, and accessibility and effectiveness of these methods vary across different regions. Some individuals may opt for fewer or no children due to social or personal considerations.

The increasing prevalence of conditions like polycystic ovarian syndrome (PCOS) contributes to the demand for point-of-care fertility testing tools:

PCOS is characterized by the abnormal production of androgens, male sex hormones, by the ovaries in women. This condition can impact ovulation and fertility, accompanied by symptoms such as irregular periods, excessive body hair, acne, weight gain, and insulin resistance. Women with PCOS may face challenges in becoming pregnant due to irregular or absent ovulation. Point-of-care fertility testing tools like ovulation prediction kits and fertility monitors empower women with PCOS to monitor their ovulation patterns and identify fertile days. Additionally, women with PCOS can use pregnancy tests and home blood pressure monitors for confirming pregnancy and monitoring health during pregnancy, reducing the risks of complications such as preterm delivery, gestational diabetes, and preeclampsia.

Global Point of Care Fertility Testing Market Challenges:

Factors impeding the demand for fertility test kits may decelerate the market's growth:

The fertility and pregnancy test sector witness intense competition, with numerous established national and regional firms striving for market supremacy. This scenario can lead to challenges such as confusion and trust issues, prompting consumers to opt for alternative laboratory test brands. Additionally, healthcare professionals often prefer laboratory diagnoses over home testing kits. Unreliable outcomes, including false positives and negatives, discourage some consumers from choosing home pregnancy tests, resulting in reduced product sales and serving as a substantial market constraint for quick test kits in the fertility and pregnancy product category. Limited awareness of fertility and pregnancy fast test kits and financial constraints preventing product purchase also contribute to somewhat restraining the global market's expansion. The resistance to adopting these products in potentially lucrative markets suggests obstacles to market enlargement.

COVID-19 Impact on Global Point of Care Fertility Testing Market:

COVID-19 has left a lasting impact on various sectors, including healthcare. Supply shortages and delayed laboratory visits have hindered daily diagnostic test procedures. The market for fertility and pregnancy quick test kits was expected to witness significant expansion as the demand for self-test kits, including midstream kits, and point-of-care kits surged. The preference to stay at home during the pandemic, rather than visiting hospitals, fueled this trend. For instance, Apollo Pharmacy reported over a 50% increase in sales in India, which was linked to the use of pregnancy quick test kits during the COVID-19 period. The market is anticipated to continue expanding, with fertility and pregnancy fast test kits gaining more reliance from consumers over the projection period.

Global Point of Care Fertility Testing Market Recent Developments:

In June 2021: The introduction of bioMérieux's REVEAL quick AST system for specific diagnostics in Europe strengthened the quick testing kits market in the European region.

Global Point of Care Fertility Testing Market Segmentation: By Type

• Human chorionic Gonadotropin (HCG) urine test

• FSH urine test

• Human chorionic Gonadotropin (HCG) blood test

• Luteinizing hormone (LH) urine test

The most precise and sensitive test for early pregnancy detection is the human chorionic gonadotropin (HCG) urine test. It assesses the levels of Human Chorionic Gonadotropin (HCG) in a person's urine to determine pregnancy. HCG is only produced during pregnancies, making it a reliable indicator of pregnancy. The human chorionic gonadotropin (HCG) urine test holds the highest popularity in the market.

The urine test for luteinizing hormone (LH) is expected to witness the fastest growth. This test measures hormones like LH, FSH, estrogen, and progesterone, providing insights into pregnancy and fertility. It is valuable for identifying infertility issues such as polycystic ovarian syndrome and abnormal ovaries. The process involves collecting urine samples at specific intervals during the menstrual cycle to assess overproduction of estrogen, lack of egg release, or other forms of anovulation problems.

Global Point of Care Fertility Testing Market Segmentation: By Fertility Tests

• Line-Indicator

• Digital

Line-indicator tests represent the fastest-growing segment in the global point-of-care fertility testing market. Traditional fertility tests utilize color-changing lines to indicate a woman's reproductive status. These tests often detect the luteinizing hormone (LH) surge, occurring just before ovulation. The LH surge signals the woman's most fertile period for conception.

Digital tests are anticipated to dominate the worldwide point-of-care fertility testing market. Digital testing is more convenient and user-friendly compared to line-indicator tests. The digital display eliminates the need for interpreting color lines, reducing the likelihood of errors. Digital tests provide a modern and clear representation of reproductive status. While they still detect the LH surge, the results are presented digitally, making it easier for consumers to understand, such as "high fertility" or "peak fertility."

Global Point of Care Fertility Testing Market Segmentation: By Distribution Channel

• Hypermarkets & supermarkets

• Gynaecology & fertility clinics

• Pharmacy

• Online sales

Gynaecology and fertility clinics use point-of-care (POC) pregnancy and fertility tests to deliver rapid results and ensure that patients can receive accurate diagnoses conveniently. Both blood and urine tests can identify pregnancy, but urine tests are simpler to collect, saving time for women facing difficulties in blood drawing.

Hypermarkets and supermarkets serve as locations for early pregnancy detection through pregnancy and fertility testing. These tests monitor levels of the human chorionic gonadotropin (HCG) hormone, which surges rapidly after implantation, making it detectable before other methods like blood tests or ultrasound scans. These tests help women understand the health of their pregnancies.

Global Point of Care Fertility Testing Market Segmentation: By End-User

• Hospitals & Clinics

• Research Institutes

• Diagnostic Laboratories

Hospitals and clinics are primary end-users of point-of-care fertility testing due to individuals seeking fertility testing and treatment. These medical facilities offer a comprehensive range of reproductive health treatments, including fertility testing. Hospitals often have dedicated sections or clinics for fertility care, providing various diagnostic and therapeutic options for individuals and couples dealing with reproductive issues.

Diagnostic laboratories are anticipated to be the fastest-growing sector in the global point-of-care fertility testing market. These specialized labs conduct a range of medical tests, including fertility tests, utilizing qualified specialists and advanced diagnostic tools. Diagnostic laboratories offer various fertility tests, including hormone level analysis, semen analysis, and genetic testing.

Global Point of Care Fertility Testing Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa

Approximately 88.2% of North American fertility test kit sales were concentrated in the United States. The U.S. market experienced growth in pregnancy and fertility fast test kits due to an increasing birthrate, a trend expected to persist during the forecast period. The U.S. working class significantly contributes to the demand for pregnancy and fertility fast test kits, as they often refrain from visiting doctors unless in emergencies, supporting the local market. The U.K. accounted for about 36.8% of the market in Western Europe. Growth in the region is influenced by factors such as rising demand for quick and self-testing kits, particularly among working women with limited time, increased unintended pregnancy rates, and expanding reproductive health issues. The demand for fertility and pregnancy quick test kits is rising in the UK due to an informed female population, technological advancements in fertility and pregnancy rapid test kits, and ongoing initiatives

Key Players:

1. Alere Inc.
2. Quidel Corporation
3. Prestige Brands Holdings, Inc.
4. Church & Dwight Co., Inc.
5. bioMérieux SA
6. Geratherm Medical AG
7. Abbott Laboratories
8. Procter & Gamble Co.
9. DCC Plc.
10. Swiss Precision Diagnostics GmbH